Guide
Spravato (Esketamine) Billing: A Practical Guide for Behavioral Health Practices
How to bill Spravato (esketamine) correctly: G2082/G2083 vs. S0013, REMS, prior auth, and the two-hour monitoring that drives the claim.
Overview
Getting Paid For Spravato Without The Denials
Spravato (esketamine) can be a clinical breakthrough for treatment-resistant depression. Billing for it is unlike anything else in a behavioral health practice. You’ve got REMS certification, prior authorization, the two-hour monitoring requirement and payer-specific coding rules all stacked on one visit, and a single missed step can turn a high-cost induction into a write-off. Here’s how the coding actually works, where claims fall apart, and what to confirm before your first patient ever sits down for monitoring. Rules vary by payer and state. Use this as a framework you verify, not a guarantee.
The Codes
Two Billing Models You Have To Choose Between
Here’s where most of the confusion starts: there’s no one universal way to bill Spravato. Most payers want a bundled HCPCS code that wraps the visit, the drug and the monitoring into a single line, while others want the drug billed separately under a “buy-and-bill” model alongside a standard evaluation and management (E/M) code. The right model is whatever that payer says it is. Get it wrong and you’re on one of the fastest routes to a denial.
G2082: Bundled, Lower Dose
An office or outpatient E/M visit plus the provision of up to 56 mg of esketamine and the required two hours of post-administration monitoring. This is the most common code for a standard induction or maintenance dose.
G2083: Bundled, Higher Dose
The same bundled structure as G2082, but for doses greater than 56 mg. Choosing between G2082 and G2083 comes down to the milligrams actually administered that day, so accurate dose documentation drives the code.
J0013 + E/M: Buy-And-Bill
Some commercial payers reject the bundled G-codes and instead want the drug billed separately under J0013 (esketamine, nasal spray, 1 mg) plus a standard E/M code. Here the units matter: you report the exact milligrams as J0013 units, so an 84 mg session is 84 units. J0013 replaced the temporary S0013 on January 1, 2026, which is why older remits and payer policies may still show the old code.
Confirm Before You Induct
Never assume which model a payer uses. Call and confirm the coding policy before the first induction so you bill it right from day one, because reworking denied claims later costs a lot more than the phone call.
REMS
Why Monitoring And Certification Sit At The Center
Spravato is dispensed under a federal Risk Evaluation and Mitigation Strategy (REMS) program. It can only be administered in a certified healthcare setting, the patient has to be monitored for at least two hours after each dose, and that monitoring has to be documented in the record. Those two hours matter for billing too. The bundled G-codes are built around them. If the monitoring time isn’t in your documentation, the clinical basis for the code you billed is gone, and payers will treat the claim that way.
REMS certification lets you administer the drug. It doesn’t replace payer enrollment or prior authorization. Those are separate steps, and skipping either one is a common reason induction claims get denied.
All of this sits on top of the standard behavioral health rules, so many practices fold Spravato oversight into their broader revenue cycle management workflow instead of treating it as a one-off. It’s the same discipline that keeps routine claims clean. Eligibility checks, documentation standards and denial tracking are exactly what a REMS-restricted, prior-auth-heavy therapy needs.
Get It Right
What To Lock Down Before The First Dose
Spravato almost always needs prior authorization on top of REMS enrollment, which means the work that protects your reimbursement happens well before the patient walks in. Use the steps below as a pre-induction checklist. Document each one in the chart as you go.
- Prior authorization for the specific patient, dose range and number of sessions the payer will cover.
- Confirm the payer’s coding model, bundled G2082/G2083 versus J0013 plus a separate E/M and record it in your billing notes.
- Your REMS-certified site, on file with the payer, so the claim doesn’t bounce for an unrecognized administration location.
- A documentation template that captures the dose administered and the full two-hour monitoring window, every visit.
- Reconcile drug units carefully, milligrams administered must match what you bill, whether that’s the G-code tier or J0013 units.
Denials
The Five Mistakes That Sink Spravato Claims
Denied Spravato claims usually trace back to the same short list of preventable issues. Know them going in and you can build controls into the front end, instead of chasing appeals on expensive claims later.
PA Not Obtained
The most common denial. REMS enrollment isn’t prior authorization. If the payer’s PA wasn’t secured for this patient and this course of treatment, the claim is at risk no matter how clean the documentation is.
REMS Site Not On File
When the certified administration site isn’t registered with the payer, claims can deny for an invalid location even though the care was delivered correctly. Check that the payer recognizes the site before you bill.
Monitoring Not Documented
The two-hour monitoring window is the backbone of the G-codes. Record it clearly, because if it isn’t there, payers may deny or downgrade the claim on the grounds that the documentation doesn’t support what you billed.
Wrong Model Or Unit Errors
Billing the bundled G-codes when the payer wants J0013, or reporting the wrong drug units, leads to denials and rework. Match the model to the payer and reconcile milligrams every time.
In Practice
Building Spravato Into A Repeatable Workflow
Practices that get paid consistently for Spravato don’t reinvent the process for every patient. They keep a payer-by-payer reference of coding models and PA requirements, they use one standardized monitoring template, and they track denials by reason so patterns show up early. The therapy sits where pharmacy billing meets behavioral health. It needs the same rigor as the rest of your psychiatry and behavioral health billing, and if your team already has the mental health billing fundamentals down, adding Spravato’s REMS and authorization steps is mostly process discipline. Rules shift, and they differ by plan and state. Revisit the payer reference on a schedule and verify before each new induction.
FAQ
Frequently Asked Questions
Do I Bill G2082/G2083 Or J0013 For Spravato?
It depends entirely on the payer. Most payers accept the bundled G-codes (G2082 for up to 56 mg, G2083 for more than 56 mg), which include the E/M visit, the drug, and two hours of monitoring. Some commercial payers instead require the drug billed separately under J0013 plus a standard E/M. Confirm each payer’s preferred model before the first induction.
Is REMS Enrollment The Same As Prior Authorization?
No. REMS certification allows your site to administer esketamine. It doesn’t authorize payment. Spravato almost always requires prior authorization in addition to REMS enrollment, and a missing PA is one of the most common reasons these claims are denied.
Why Do Spravato Claims Get Denied So Often?
The usual culprits are a prior authorization that was never obtained, a REMS site that isn’t on file with the payer, two-hour monitoring time that wasn’t documented, the wrong coding model for that payer, and drug-unit errors. Most of them are preventable with front-end verification and solid documentation.
What Documentation Does The Monitoring Requirement Need?
Spravato’s REMS program requires at least two hours of post-administration monitoring in a certified healthcare setting, and that monitoring has to be documented in the patient record. The G-codes are built around this window. Capture the dose and the full monitoring period at every visit, since that’s what supports the claim.
Next Step
Know What This Would Cost For Your Practice.
Every service has a published price and a written scope. If you are not sure which one fits, ask and you will be pointed at the right one.